The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

John P. Leonard

Center for Lymphoma and Myeloma

and Division of Hematology and Medical Oncology

Weill Cornell Medical College and New York Presbyterian Hospital

New York

USA

[email]@med.cornell.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, USA. 2001 - 2010
  • Oncology Services, New York Presbyterian Hospital, New York Weill Cornell Medical Center, Starr Pavilion, USA. 2003

References

  1. Novel agents for follicular lymphoma. Leonard, J.P., Martin, P. Hematology. Am. Soc. Hematol. Educ. Program (2010) [Pubmed]
  2. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Leonard, J.P., Schuster, S.J., Emmanouilides, C., Couture, F., Teoh, N., Wegener, W.A., Coleman, M., Goldenberg, D.M. Cancer (2008) [Pubmed]
  3. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Leonard, J.P., Gregory, S.A., Maloney, D.G., Vose, J.M., Younes, A., Zelenetz, A.D. Clin. Adv. Hematol. Oncol (2008) [Pubmed]
  4. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Leonard, J.P., Goldenberg, D.M. Oncogene (2007) [Pubmed]
  5. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Leonard, J.P., Friedberg, J.W., Younes, A., Fisher, D., Gordon, L.I., Moore, J., Czuczman, M., Miller, T., Stiff, P., Cheson, B.D., Forero-Torres, A., Chieffo, N., McKinney, B., Finucane, D., Molina, A. Ann. Oncol. (2007) [Pubmed]
  6. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Leonard, J.P., Furman, R.R., Coleman, M. Int. J. Cancer (2006) [Pubmed]
  7. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Leonard, J.P., Coleman, M., Ketas, J., Ashe, M., Fiore, J.M., Furman, R.R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C.L., Wegener, W.A., Horak, I.D., Goldenberg, D.M. J. Clin. Oncol. (2005) [Pubmed]
  8. New developments in immunotherapy for non-Hodgkin's lymphoma. Leonard, J.P., Furman, R.R., Ruan, J., Coleman, M. Curr. Oncol. Rep (2005) [Pubmed]
  9. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Leonard, J.P., Coleman, M., Kostakoglu, L., Chadburn, A., Cesarman, E., Furman, R.R., Schuster, M.W., Niesvizky, R., Muss, D., Fiore, J., Kroll, S., Tidmarsh, G., Vallabhajosula, S., Goldsmith, S.J. J. Clin. Oncol. (2005) [Pubmed]
  10. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Leonard, J.P., Coleman, M., Ketas, J.C., Chadburn, A., Furman, R., Schuster, M.W., Feldman, E.J., Ashe, M., Schuster, S.J., Wegener, W.A., Hansen, H.J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S.Z., Cesano, A., Goldenberg, D.M. Clin. Cancer Res. (2004) [Pubmed]
  11. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Leonard, J.P., Siegel, J.A., Goldsmith, S.J. Cancer Invest. (2003) [Pubmed]
  12. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. Leonard, J.P., Coleman, M., Ketas, J.C., Chadburn, A., Ely, S., Furman, R.R., Wegener, W.A., Hansen, H.J., Ziccardi, H., Eschenberg, M., Gayko, U., Cesano, A., Goldenberg, D.M. J. Clin. Oncol. (2003) [Pubmed]
  13. Biology and management of mantle cell lymphoma. Leonard, J.P., Schattner, E.J., Coleman, M. Curr. Opin. Oncol (2001) [Pubmed]
 
WikiGenes - Universities